AIMOVIG erenumab

Drug Class

Calcitonin gene-related peptide (CGRP) receptor antagonist

Mechanism

Erenumab is a human monoclonal antibody that selectively binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes its function to prevent migraine activation.

Approved Indication

Preventive treatment of migraine in adults.

What This Means For Patients

Aimovig is a monoclonal antibody therapy designed for the prevention of migraine in adult patients. It is administered via monthly subcutaneous injection to reduce the frequency and severity of migraine attacks. Following approvals by the FDA, EMA, and China NMPA, it is available for international patients in the Hainan Boao Lecheng pilot zone under special import policies.

Regulatory Approvals

• FDA — approved (2018) — label
• EMA — approved (2018) — source
• NMPA — approved (2023) — source

Pivotal Clinical Evidence

• STRIVE — Goadsby et al., N Engl J Med 2017 (NCT02456740) — DOI

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig
• https://www.novartis.com/news/media-releases/novartis-announces-aimovig-approved-china-preventive-treatment-migraine